12 research outputs found
Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction
Nimodipine is a 1,4-dihydropyridine derivative that shows a preferential
cerebrovascular activity in experimental animals. Clinical data suggest that
nimodipine has a beneficial effect on the neurologic outcome of patients
suffering an acute ischemic stroke. Our double-blind placebo-controlled
multicenter trial was designed to assess the effects of oral nimodipine on the
mortality rate and neurologic outcome of patients with an acute ischemic stroke.
One hundred sixty-four patients were randomly allocated to receive either
nimodipine tablets (30 mg q.i.d.) or identical placebo tablets for 28 days.
Treatment was always started less than or equal to 48 hours after the acute
event. The Mathew Scale, slightly modified by Gelmers et al, was used for
neurologic assessment. Mortality rate and neurologic outcome after 28 days were
used as evaluation criteria. We considered 123 patients to be valid for the
analysis of efficacy. Mortality rates did not differ significantly between
groups. Neurologic outcome after 28 days of therapy did not differ between
groups. However, when only those patients most likely to benefit from any
intervention (Mathew Scale sum score of less than or equal to 65 at baseline)
were analyzed separately in post hoc-defined subgroups, the nimodipine-treated
subgroups showed a significantly better neurologic outcome. This result suggests
that some patients with acute ischemic stroke will benefit from treatment with
nimodipine tablets
RICORS2040 : The need for collaborative research in chronic kidney disease
Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase
The Charlotte Project: Recommendations for patient-reported outcomes and clinical parameters in Dravet syndrome through a qualitative and Delphi consensus study
Objective: The appropriate management of patients with Dravet Syndrome
(DS) is challenging, given the severity of symptoms and the burden of the
disease for patients and caregivers. This study aimed to identify, through
a qualitative methodology and a Delphi consensus-driven process, a set
of recommendations for the management of DS to guide clinicians in the
assessment of the clinical condition and quality of life (QoL) of DS patients,
with a special focus on patient- and caregiver-reported outcomes (PROs).
Methods: This study was conducted in five phases, led by a multidisciplinary
scientific committee (SC) including pediatric neurologists, epileptologists, a
neuropsychologist, an epilepsy nurse, and members of DS patient advocates.
In phases 1 and 2, a questionnaire related to patients’ QoL was prepared
and answered by caregivers and the SC. In phase 3, the SC generated,
based on these answers and on a focus group discussion, a 70-item Delphi
questionnaire, covering six topic categories on a nine-point Likert scale.
In phase 4, 32 panelists, from dierent Spanish institutions and with a
multidisciplinary background, answered the questionnaire. Consensus was
obtained and defined as strong or moderate if ≥80% and 67–79% of panelists,
respectively, rated the statement with ≥7. Phase 5 consisted of the preparation
of the manuscript.
Results: The panelists agreed on a total of 69 items (98.6%), 54
(77.14%), and 15 (21.43%) with strong and moderate consensus, respectively.
Frontiers in Neurology 01 frontiersin.or
Aledo-Serrano et al. 10.3389/fneur.2022.975034
The experts’ recommendations included the need for frequent assessment of
patient and caregivers QoL parameters. The experts agreed that QoL should be
assessed through specific questionnaires covering dierent domains. Likewise,
the results showed consensus regarding the regular evaluation of several
clinical parameters related to neurodevelopment, attention, behavior, other
comorbidities, and sudden unexpected death in epilepsy (SUDEP). A consensus
was also reached on the instruments, specific parameters, and caregivers’
education in the routine clinical management of patients with DS.
Conclusions: This consensus resulted in a set of recommendations for
the assessment of clinical and QoL parameters, including PROs, related to
the general evaluation of QoL, neurodevelopment, attention, behavior, other
comorbidities aecting QoL, SUDEP, and QoL of caregivers/relatives and
patients with D
Near-intrinsic energy resolution for 30-662 keV gamma rays in a high pressure xenon electroluminescent TPC
We present the design, data and results from the NEXT prototype for Double Beta and Dark Matter (NEXT-DBDM) detector, a high-pressure gaseous natural xenon electroluminescent time projection chamber (TPC) that was built at the Lawrence Berkeley National Laboratory. It is a prototype of the planned NEXT-100 136Xe neutrino-less double beta decay (0νββ) experiment with the main objectives of demonstrating near-intrinsic energy resolution at energies up to 662 keV and of optimizing the NEXT-100 detector design and operating parameters. Energy resolutions of ∼1% FWHM for 662 keV gamma rays were obtained at 10 and 15 atm and ∼5% FWHM for 30 keV fluorescence xenon X-rays. These results demonstrate that 0.5% FWHM resolutions for the 2459 keV hypothetical neutrino-less double beta decay peak are realizable. This energy resolution is a factor 7-20 better than that of the current leading 0νββ experiments using liquid xenon and thus represents a significant advancement. We present also first results from a track imaging system consisting of 64 silicon photo-multipliers recently installed in NEXT-DBDM that, along with the excellent energy resolution, demonstrates the key functionalities required for the NEXT-100 0νββ searc
Methane on Mars: New insights into the sensitivity of CH4 with the NOMAD/ExoMars spectrometer through its first in flight calibration
info:eu-repo/semantics/publishe
Deep Underground Neutrino Experiment (DUNE) Near Detector Conceptual Design Report
International audienceThe Deep Underground Neutrino Experiment (DUNE) is an international, world-class experiment aimed at exploring fundamental questions about the universe that are at the forefront of astrophysics and particle physics research. DUNE will study questions pertaining to the preponderance of matter over antimatter in the early universe, the dynamics of supernovae, the subtleties of neutrino interaction physics, and a number of beyond the Standard Model topics accessible in a powerful neutrino beam. A critical component of the DUNE physics program involves the study of changes in a powerful beam of neutrinos, i.e., neutrino oscillations, as the neutrinos propagate a long distance. The experiment consists of a near detector, sited close to the source of the beam, and a far detector, sited along the beam at a large distance. This document, the DUNE Near Detector Conceptual Design Report (CDR), describes the design of the DUNE near detector and the science program that drives the design and technology choices. The goals and requirements underlying the design, along with projected performance are given. It serves as a starting point for a more detailed design that will be described in future documents